Gynecological radiotherapy in people living with human immunodeficiency virus: a semi-systematic literature review
- 7 March 2022
- journal article
- review article
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 32 (3) , 429-435
Abstract
Appropriate diagnosis and treatment of gynecological cancers in people living with human immunodeficiency virus (HIV) remains a clinical challenge given rapid changes in both HIV and cancer management and a lack of prospective clinical trial data inclusive of the HIV population. A semi-systematic literature review was performed to identify published studies addressing risk factors, screening, treatment efficacy, treatment toxicity, and prognosis for people living with HIV diagnosed with gynecological malignancies, with a focus on radiotherapy and cervical cancer, given the relative paucity of literature on uterine, ovarian, and vulvovaginal cancers in people living with HIV. People living with HIV are more likely to be co-infected with human papilloma virus and more likely to develop human papilloma virus-associated malignancies. People living with HIV are less likely to receive cancer treatment compared with HIV-uninfected cancer patients, even after adjusting for differences in clinical features and sociodemographic variables. The literature on cervical cancer outcomes is mixed, with some studies demonstrating that people living with HIV have inferior treatment tolerability, response rates, and survival following chemoradiotherapy, and others showing no difference in these outcomes, particularly in patients receiving antiretroviral therapy. Importantly, even in the series showing inferior outcomes in people living with HIV, there were long-term survivors after administration of curative therapy. Consistent with published cancer management guidelines, people living with HIV diagnosed with gynecological cancers should be treated with standard cancer therapy. Co-management with the patient’s HIV specialist is critical to avoid overlapping toxicities and provide optimal supportive care. The morbidity and mortality caused by gynecologic cancers in this population can be mitigated by early diagnosis, appropriate treatment delivery including inclusion of people with HIV in cancer clinical trials, and diligent HIV management.Keywords
This publication has 40 references indexed in Scilit:
- Analysis of Factors Contributing to the Low Survival of Cervical Cancer Patients Undergoing Radiotherapy in KenyaPLOS ONE, 2013
- Effect of Human Immunodeficiency Virus Infection on the Prevalence and Incidence of Vaginal Intraepithelial NeoplasiaObstetrics & Gynecology, 2012
- Completion of and early response to chemoradiation among human immunodeficiency virus (HIV)‐positive and HIV‐negative patients with locally advanced cervical carcinoma in South AfricaCancer, 2011
- Risk of Human Papillomavirus–Associated Cancers Among Persons With AIDSJNCI: Journal of the National Cancer Institute, 2009
- Long‐term incidence of cervical cancer in women with human immunodeficiency virusCancer, 2009
- The Impact of HIV Status and Type on the Clearance of Human Papillomavirus Infection among Senegalese WomenThe Journal of Infectious Diseases, 2007
- HIV impact on acute morbidity and pelvic tumor control following radiotherapy for cervical cancerGynecologic Oncology, 2006
- Invasive vulvar cancer in a woman with human immunodeficiency virus: Case report and review of the literatureGynecologic Oncology, 2005
- Rapid Progression of Primary Vaginal Squamous Cell Carcinoma in a Young HIV-Infected WomanGynecologic Oncology, 2000
- First reported case of endometrial carcinoma in association with HIV infectionInternational Journal of Gynecological Cancer, 1999